Day: April 13, 2021

Chemistry can be defined as the study of matter and the changes it undergoes. You¡¯ll sometimes hear it called the central science because it is the connection between physics and all the other sciences, starting with biology. 135236-72-5, Name is Calcium 3-hydroxy-3-methylbutanoate, molecular formula is , belongs to Benzisoxazole compound. In a document, author is Kociolek, Martin George, HPLC of Formula: C10H18CaO6.

Benzisoxazole 2-oxides as novel UV absorbers and photooxidation inhibitors

Compounds with strong absorptions in the ultraviolet (UV) region of the spectrum, particularly the UVA and UVB, have seen much interest as UV screeners or absorbers in a wide variety of commercial products. A series of benzisoxazole 2-oxides have been synthesized and characterized by UV-vis spectroscopy. A number of derivatives have been shown to posses moderate to strong molar absorption coefficients in the UVB range (ca. 300nm), the strongest being those derived from benzophenones. Three other derivatives containing additional electron withdrawing groups showed strong molar absorption coefficients in the UVA (ca. 340nm). Solvent effects on the parent derivatives show changes in the molar absorption coefficients with little changes in the max values. Preliminary studies of these compounds as potential additives to prevent photooxidation of polystyrene showed considerable inhibition of polymer degradation with the parent unsubstituted benzisoxazole 2-oxide compounds being the most effective. Copyright (c) 2013 John Wiley & Sons, Ltd.

If you are hungry for even more, make sure to check my other article about 135236-72-5, HPLC of Formula: C10H18CaO6.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels. 52356-01-1, Name is 2-Hydrazinobenzoic acid hydrochloride, molecular formula is C7H9ClN2O2. In an article, author is Sano, Hiromi,once mentioned of 52356-01-1, Product Details of 52356-01-1.

Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson’s disease

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by the loss of nigrostriatal dopaminergic neurons and consequent motor dysfunction. Zonisamide (1,2-benzisoxazole-3-methanesulfonamide), which was originally developed as an antiepileptic drug, has been found to have therapeutic benefits for PD. However, the pharmacological mechanisms behind the beneficial actions of zonisamide in PD are not fully understood. Here, we investigated the neuroprotective effects of zonisamide on nigrostriatal dopaminergic neurons of the Engrailed mutant mouse, a genetic model of PD. Chronic administration of zonisamide in Engrailed mutant mice was shown to improve the survival of nigrostriatal dopaminergic neurons compared with that under saline treatment. In addition, dopaminergic terminals in the striatum and the motor function were improved in zonisamide-treated Engrailed mutant mice to the levels of those in control mice. To clarify the mechanism behind the neuroprotective effects of zonisamide, the contents of neurotrophic factors were determined after chronic administration of zonisamide. Brain-derived neurotrophic factor content was increased in the striatum and ventral midbrain of the zonisamide-treated mice compared to saline-treated mice. These findings imply that zonisamide reduces nigrostriatal dopaminergic cell death through brain-derived neurotrophic factor signaling and may have similar beneficial effects in human parkinsonian patients as well.

Interested yet? Keep reading other articles of 52356-01-1, you can contact me at any time and look forward to more communication. Product Details of 52356-01-1.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Related Products of 600-18-0, Catalysts allow a reaction to proceed via a pathway that has a lower activation energy than the uncatalyzed reaction. 600-18-0, Name is 2-Oxobutanoic acid, SMILES is CCC(=O)C(O)=O, belongs to Benzisoxazole compound. In a article, author is RICCI, A, introduce new discover of the category.

AUXIN-LIKE ACTIVITY OF 1,2-BENZISOXAZOLE-3-ALKANOIC ACIDS

A series of benzisoxazole-alkanoic acids, differing in the length of the side-chain, have been synthesized and their activity tested on pea stem elongation, flax root growth and shoot regeneration from tomato cotyledon explants. All compounds had little or no effect on cell elongation or root growth, but a stimulating effect on shoot induction in vitro, thus showing that their activity, like that of 1,2-benzisoxazole acetic acid, is partly independent of the side-chain and is linked to the structure of the benzisoxazolic ring.

Related Products of 600-18-0, One of the oldest and most widely used commercial enzyme inhibitors is aspirin, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 600-18-0.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Chemistry is an experimental science, Application In Synthesis of Calcium 3-hydroxy-3-methylbutanoate, and the best way to enjoy it and learn about it is performing experiments.Introducing a new discovery about 135236-72-5, Name is Calcium 3-hydroxy-3-methylbutanoate, molecular formula is C10H18CaO6, belongs to Benzisoxazole compound. In a document, author is Richardson, C.

Synthesis and complexes of the first chelating ligand containing a 1,2-benzisoxazole subunit

The new ligand 3-(2-pyridyl)-1,2-benzisoxazole (3) was prepared in five steps from readily available starting materials. It represents the first example of a chelating ligand containing a 1,2-benzisoxazole group and readily forms complexes with palladium(II), copper(II) and ruthenium(II). An X-ray crystal structure of the copper complex, trans-Cu(3)(2)(NO3)(2), is the first reported structure of a complex containing a 1,2-benzisoxazole. (C) 2000 Elsevier Science S.A. All rights reserved.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 135236-72-5, in my other articles. Application In Synthesis of Calcium 3-hydroxy-3-methylbutanoate.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

In an article, author is Yagi, K, once mentioned the application of 636-61-3, Formula: C4H6O5, Name is (R)-2-Hydroxysuccinic acid, molecular formula is C4H6O5, molecular weight is 134.0874, MDL number is MFCD00004245, category is Benzisoxazole. Now introduce a scientific discovery about this category.

Overview of Japanese experience-controlled and uncontrolled trials

Zonisamide is a new type of benzisoxazole derivative, first marketed in Japan in 1989. This study analyzed: (1) the drug’s efficacy by seizure and epilepsy type in a total of 1008 patients treated during the development of zonisamide in Japan; (2) the effectiveness of zonisamide for 726 newly-diagnosed patients treated with zonisamide postmarketing; and (3) 50 patients with generalized epilepsies and epileptic syndromes (idiopathic generalized epilepsies, symptomatic generalized epilepsies, Lennox-Gastaut syndrome, Doose syndrome, and West syndrome), and 19 patients with undetermined epilepsies and specific syndromes (refractory grand mat in childhood, severe myoclonic epilepsy in infancy, other undetermined epilepsy, familial. essential myoclonic epilepsy, and mitochondrial encephalomyopathy with ragged-red fibers). Analysis of study results showed that among all patients treated, zonisamide was highly effective for the treatment of idiopathic generalized epilepsy, temporal lobe epilepsy, and other partial epilepsies. The compound was also effective for other symptomatic generalized epilepsies. In 50 patients with generalized epilepsies, and 19 with undetermined epilepsies and specific syndromes, seizure frequency was reduced by >50% with monotherapy or two-drug therapy with zonisamide. Zonisamide was effective not only for partial epilepsies and generalized epilepsies but also for undetermined epilepsies and specific syndromes such as myoclonus epilepsy. (C) 2004 BEA Trading Ltd. Published by Elsevier Ltd. All. rights reserved.

Interested yet? Read on for other articles about 636-61-3, you can contact me at any time and look forward to more communication. Formula: C4H6O5.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

98-89-5, Name is Cyclohexanecarboxylic acid, molecular formula is C7H12O2, HPLC of Formula: C7H12O2, belongs to Benzisoxazole compound, is a common compound. In a patnet, author is Grue-Sorensen, G, once mentioned the new application about 98-89-5.

Synthesis of tritium labelled L783483 – a PPAR delta ligand

The potent peroxisome proliferator-activated receptor (PPAR) 6 ligand L783483 (3-chloro-4-(3-(7-propyl-3-trifluoromethyl-benzisoxazol-6-oxy)propylsulfanyl)phenylacetic acid) has been labelled with tritium via selective tritium/bromine exchange of 5-bromo-6-(3-bromopropyloxy)-7-propyl-3-trifluoromethyl-benzisoxazole. [H-3]-L783483 had a specific activity of 529 GBq/mmol (14.3 Ci/mmol) and a radiochemical purity of 98%. Copyright (C) 2003 John Wiley Sons, Ltd.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 98-89-5 help many people in the next few years. HPLC of Formula: C7H12O2.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Chemistry is the science of change. But why do chemical reactions take place? Why do chemicals react with each other? The answer is in thermodynamics and kinetics, Application In Synthesis of 3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid, 83249-10-9, Name is 3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid, SMILES is O=C(C1(C2)CC2(C(OC)=O)C1)O, belongs to Benzisoxazole compound. In a document, author is GARCIA, G, introduce the new discover.

RISPERIDONE – AN ATYPICAL AGENT APPROVED AS 1ST-LINE THERAPY FOR MANAGING MANIFESTATIONS OF PSYCHOTIC DISORDERS

Risperidone, a benzisoxazole derivative, was recently approved by the FDA for the management of psychotic disorders. It joins clozapine as the second antipsychotic agent to become available that possesses both dopaminergic and serotoninergic blocking activities. Risperidone has been shown to improve the positive and negative symptoms of schizophrenia in clinical trials. The drug can be used as a first-line agent and trials are currently being conducted to establish its benefit in treatment-refractory patients. Risperidone is associated with a low incidence of extrapyramidal symptoms, has not been associated with tardive dyskinesia, and does not require hematological monitoring. The availability of risperidone represents progress not only in the pharmacotherapy of schizophrenia, but also in the understanding of the pathophysiology of this disorder.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 83249-10-9 is helpful to your research. Application In Synthesis of 3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels. 526-83-0, Name is 2,3-Dihydroxysuccinic acid, molecular formula is C4H6O6. In an article, author is GARCIA, G,once mentioned of 526-83-0, Recommanded Product: 2,3-Dihydroxysuccinic acid.

RISPERIDONE – AN ATYPICAL AGENT APPROVED AS 1ST-LINE THERAPY FOR MANAGING MANIFESTATIONS OF PSYCHOTIC DISORDERS

Risperidone, a benzisoxazole derivative, was recently approved by the FDA for the management of psychotic disorders. It joins clozapine as the second antipsychotic agent to become available that possesses both dopaminergic and serotoninergic blocking activities. Risperidone has been shown to improve the positive and negative symptoms of schizophrenia in clinical trials. The drug can be used as a first-line agent and trials are currently being conducted to establish its benefit in treatment-refractory patients. Risperidone is associated with a low incidence of extrapyramidal symptoms, has not been associated with tardive dyskinesia, and does not require hematological monitoring. The availability of risperidone represents progress not only in the pharmacotherapy of schizophrenia, but also in the understanding of the pathophysiology of this disorder.

Interested yet? Keep reading other articles of 526-83-0, you can contact me at any time and look forward to more communication. Recommanded Product: 2,3-Dihydroxysuccinic acid.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

Related Products of 75-98-9, Children learn through play, and they learn more than adults might expect. Science experiments are a great way to spark their curiosity, 75-98-9, Name is Pivalic acid, SMILES is CC(C)(C)C(O)=O, belongs to Benzisoxazole compound. In a article, author is Seino, M, introduce new discover of the category.

Review of zonisamide development in Japan

Zonisamide is a benzisoxazole-based compound first synthesized in the early 1970s by the research laboratories of Dainippon Pharmaceutical Company in Osaka, Japan. Identified as an anticonvulsant during exploratory research, zonisamide has since been characterized as having broad-spectrum antiepitepsy and neuroprotective effects. Early clinical studies in Japan demonstrated that zonisamide has a long elimination half-life and is well tolerated; Phase II and III clinical trials established the drug’s efficacy and safety for the treatment of partial and generalized seizures. In 1989, zonisamide was approved and marketed in Japan under the trade name of Excegran(R). Data from postmarketing surveillance studies and clinical observations over 10 years of use have continued to support zonisamide’s efficacy and safety, identified its usefulness as monotherapy, and characterized its effectiveness for various seizure types and epilepsy syndromes. (C) 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.

Related Products of 75-98-9, One of the oldest and most widely used commercial enzyme inhibitors is aspirin, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 75-98-9.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics

In an article, author is Okada, M, once mentioned the application of 99-06-9, Name is 3-Hydroxybenzoic acid, molecular formula is C7H6O3, molecular weight is 138.12, MDL number is MFCD00002506, category is Benzisoxazole. Now introduce a scientific discovery about this category, Category: Benzisoxazole.

Effects of zonisamide on dopaminergic system

Effects of zonisamide (ZNS) on extracellular dopamine (DA), its precursor 3,4-dihydroxyphenylalanine (DOPA), its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) levels in the striatum as well as hippocampus of freely moving rats were studied. Intracellular DA, DOPA, DOPAC and HVA levels, as well as DOPA accumulation as an index of tyrosine hydroxylase activity in the rat brain in vivo, DA re-uptake in the striatum and hippocampus, and monoamine oxidase (MAO) activities were also determined. Acute administrations of therapeutic ZNS doses (20 and 50 mg/kg) increased striatal extracellular DOPA levels, intracellular striatal and hippocampal DOPA levels, and stimulated DOPA accumulation in both brain regions. ZNS also increased striatal and hippocampal intracellular as well as extracellular DA and MIA Levels, but decreased those of DOPAC levels. Chronic (3 weeks) administrations of therapeutic ZNS doses (20 and 50 mg/kg/day) increased intracellular DA, DOPA, DOPAC and HVA levels in striatum and hippocampus. ZNS-induced changes were greater in intracellular levels than in extracellular levels. Acute and chronic supratherapeutic ZNS dose (100 mg/kg) administration decreased intracellular levels of all substances detectable in both brain regions, and inhibited DOPA accumulation. Both subtypes of MAO (type A and type B) activities were weakly inhibited by ZNS. ZNS showed no effect on DA re-uptake in striatum nor in hippocampus. These results suggest that therapeutic ZNS doses increase DOPA accumulation as well as both intracellular and extracellular DA, DOPA and HVA levels. However, such doses also decrease extracellular and intracellular DOPAC levels by enhancing DA synthesis and/or by selectively inhibiting MAO-B activities. In addition, chronic therapeutic ZNS dose administration enhances DA synthesis, which results in increased intracellular DA, its precursor and its metabolites levels. On the other hand, both acute and chronic supratherapeutic ZNS dose administrations inhibit DA turnover. These ZNS effects on DA metabolism are at least partly involved in the mechanisms of action of ZNS.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 99-06-9, Category: Benzisoxazole.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics